Drugs / GNKG168
GNKG168
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04952272 | Mar 2021 → Jun 2029 expected | hepatocellular carcinoma, lung cancer | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT01743807 | Mar → Jul 2014 | acute lymphoblastic leukemia, acute myeloid leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT01035216 | Sep 2009 → Nov 2013 | leukemia | SBI Biotech Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06047015 | Jul 2025 → Dec 2027 expected | metastasis from malignant tumor of colon | University of Saskatchewan | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00190424 | Sep 2005 → Oct 2008 | glioblastoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNKG168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01743807 ↗ |
| Known as | CpG Oligodeoxynucleotides | “IRE plus Checkpoint Inhibitor plus CpG Oligodeoxynucleotides (CpG-ODN)” NCT06047015 ↗ |
| Known as | CPG-685 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297962 ↗ |
| Known as | CpG-ODN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00190424 ↗ |
| Action | Activate | “GNKG168 is a Toll-like receptor (TLR) agonist.” NCT01743807 ↗ |
| Modality | Oligonucleotide (other) | “CpG ODN” NCT01035216 ↗ |
| Route | Intravenous | “60 minute IV infusion” NCT01035216 ↗ |